25, 3% risikoreduktion i fordobling af serumkreatinin (p=0, 006); 28, 6% risikoreduktion i kronisk nyresvigt (p=0, 002); 19, 9% risikoreduktion i kronisk nyresvigt eller død (p=0, 009); 21, 0% risikoreduktion i fordobling af serumkreatinin eller kronisk nyresvigt (p=0, 01).
25.3% risk reduction for doubling of the serum creatinine (p = 0.006); 28.6% risk reduction for end-stage renal failure (p = 0.002); 19.9% risk reduction for end-stage renal failure or death (p = 0.009); 21.0% risk reduction for doubling of serum creatinine or end-stage renal failure (p = 0.01).